Drugs. 2003;63(20):2203-12; discussion 2213-4. doi: 10.2165/00003495-200363200-00004.


black triangle Tadalafil is a selective phosphodiesterase type 5 inhibitor that is effective in men with mild-to-severe erectile dysfunction (ED), including those with diabetes mellitus. black triangle The improvement in the erectile function domain score on the International Index of Erectile Function (IIEF) and the percentage of sexual intercourse attempts marked by successful vaginal penetration and completion was significantly greater with on-demand (not more than once daily) tadalafil 10 or 20 mg than placebo in trials of 12 weeks' duration. Improvement in scores on other domains of the IIEF and the percentage of positive responses to a Global Assessment Question measuring erection improvement were also significantly greater with on-demand tadalafil than placebo. black triangle The adverse events associated with tadalafil were generally mild to moderate and decreased in frequency with continued administration. The most commonly reported adverse events were headache and dyspepsia. The incidence of cardiovascular adverse events was not significantly different in tadalafil or placebo recipients.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Review

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Carbolines / adverse effects
  • Carbolines / pharmacokinetics
  • Carbolines / therapeutic use*
  • Clinical Trials as Topic
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Diabetes Complications
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Erectile Dysfunction / complications
  • Erectile Dysfunction / drug therapy*
  • Humans
  • Male
  • Phosphodiesterase Inhibitors / adverse effects
  • Phosphodiesterase Inhibitors / pharmacokinetics
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Phosphoric Diester Hydrolases / metabolism*
  • Tadalafil
  • Treatment Outcome


  • Carbolines
  • Phosphodiesterase Inhibitors
  • Tadalafil
  • Phosphoric Diester Hydrolases
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human